Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
about
Iron chelation and multiple sclerosisIron chelation therapy in myelodysplastic syndromes: where do we stand?Iron dosing in kidney disease: inconsistency of evidence and clinical practice.HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional studyResponse of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusionsImpact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndromeHematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.Influence of endodontic treatment on systemic oxidative stress.Myelodysplastic Syndromes and Iron Chelation TherapyDeferasirox: pharmacokinetics and clinical experience.Efficacy and safety of deferasirox in myelodysplastic syndromes.Iron chelation in the treatment of cancer: a new role for deferasirox?Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.Deferasirox reduces oxidative stress in patients with transfusion dependency.The association of transfusion status with antioxidant enzymes and malondialdehyde level in Nigerians with sickle cell disease.Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?Soluble fms-Like Tyrosine Kinase 1 as a Link Between Angiogenesis and Endothelial Dysfunction in Pediatric Patients With β-Thalassemia Intermedia.Iron-chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formation.Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study.The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome
P2860
Q27001743-EEDD7886-82AA-4A6B-B2F6-DC0432460C3CQ27011747-34A69D27-DB0E-4FC7-8343-56A343DF9E30Q35022235-92E3DC6D-68B3-434C-8269-8FAA9F4569AAQ35332467-A98551AA-91F5-4323-92A8-74123593D352Q35589756-13CB1491-11A5-4E1D-A4A7-112C7756E0EFQ35629409-B8C4C6AD-F8BB-4CAE-AFBB-1E6F7F6FD688Q35743810-AFE717B4-B4BC-47A1-9F21-4C8E5426D047Q36216214-CC09E5BA-79F5-4917-952B-E763182F0D96Q36420464-623EB225-EEB0-4308-9014-D7EC14E23331Q37326129-93F9EAAC-F1EF-4FDF-9F6D-9244B33059AEQ37434248-F4D98456-D0DB-43C1-9408-97AB16250678Q37677229-A951321F-D4CC-4286-8342-A30D4D759899Q37969225-DA42FF53-301D-4792-82D2-72AED73EDF57Q38082464-0EBA6377-A2F2-42ED-8231-DDBABF17BE85Q38112400-AA2C9FA6-407A-4F6B-B5C9-7DCFDBD27127Q38196963-E0ED59D4-A52F-4E74-A077-2484F114A30CQ38368123-C734D1D9-7803-4673-9431-69EC971F4AB6Q38427850-5ADDEA96-E1A8-4BB1-8C51-DC2E206B7F2CQ38832241-AD6FC343-1271-4017-AB12-0E5626D633AEQ41323380-83B3172A-2CD3-487D-9A19-8EF7F5787796Q41773526-27E74ACE-CFF4-41F2-9335-E05FAED7B218Q41879690-0A2ACD2A-BF79-4D2D-8E9F-7B094B56CDA4Q42645802-7DBB55C2-0C5C-4019-AC76-60E59DF10946Q42783336-78BC6D5C-0DD9-4339-B5FA-82A3F71A07C7Q43756622-5BF4D09C-2BCB-4F08-8375-C444AB7DD208Q45971495-654D58C5-3A06-4FE1-B1D3-7C034C2C5F60Q46223563-F6CA46AB-CBCE-495F-A57B-B1D8A82583CAQ46528802-DEA962AF-7B4D-4913-B8F8-5EBC430D2505Q46729480-F2118CCF-0CA8-416D-AD93-538E02FADFD8Q46751055-F7164EC5-6CA5-4F98-9865-2609B71FAB72Q48186090-5C56E1CB-62E6-4492-B6D9-E851EFA05BDAQ50484280-6E3E4ED9-FB68-40DC-B715-2541A0F8A189Q56489127-B4451BBF-C75D-441C-A530-81C13E61A35E
P2860
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@en
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@nl
type
label
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@en
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@nl
prefLabel
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@en
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@nl
P2093
P2860
P1433
P1476
Changes in parameters of oxida ...... ith myelodysplastic syndromes.
@en
P2093
Drorit Merkel
Eitan Fibach
Eliezer A Rachmilewitz
Galit Perez-Avraham
Hussam Ghoti
Sigal Grisariu
P2860
P304
P356
10.3324/HAEMATOL.2010.024992
P577
2010-04-26T00:00:00Z